Silvia Coronel , Shamili Allam, Neha Teekappanavar, Ahmed Abdelhalim, Sivagini Ganesh, Wafaa Elatre, Michael Koss, Janice Liebler, Richard Barbers, Alison Wilcox, Bonnie Garon, Zea Borok, Billy Peng and Ahmet Baydur*
Background: The 2019 update by the ISHLT of classification for CLAD includes a mixed and undefined phenotype.
Objectives: Assess (a) frequency phenotypes (per ISHLT) with emphasis on double lung transplants (DLTxs), (b) concordance spirometry with imaging and transbronchial biopsy findings, (c) mortality rates amongst phenotypes.
Methods: Single-center retrospective study of adult patients. Time from transplant to CLAD and mortality amongst phenotypes compared by ANOVA adjusted for age, gender and BMI.
Results: Of 360 patients, 96 (27%) met criteria for CLAD (57 DLTx). Seventy-four (77%) experienced combined FEV1 and FVC decline. In DLTxs, onset of FEV1 decline (n=12) occurred 10 months earlier than for FVC (n=4) and 5 months before simultaneous onset of FVC and FEV1 decline (n=41). Amongst DLTxs, largest cohort was mixed group (n=30, 53%); RAS phenotype second largest (n=16, 28%). Median onset of CLAD: 30 months for BOS and mixed categories (combined n=34); 48 months for RAS (n=16). Time to death following DLTx: longest in BOS, shortest in RAS, intermediate in mixed phenotypes.
Conclusion: CLAD occurs in more than one-quarter of patients; three-fourths exhibit concurrent decline in FEV1 and FVC. Imaging detects changes when biopsy findings are mild or not identified and often do not reflect spirometric changes.
ఈ కథనాన్ని భాగస్వామ్యం చేయండి
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 